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48Second Primary Cancers in Patients with
Invasive and In Situ Squamous Cell Skin
Carcinoma, Kaposi Sarcoma, and Merkel Cell
Carcinoma: Role for Immune Mechanisms?
Subhayan Chattopadhyay1, Akseli Hemminki2,3, Asta Fo¨rsti1,4, Kristina Sundquist4,5,6,7,
Jan Sundquist4,5,6,7 and Kari Hemminki1,4Second primary cancers (SPCs) are becoming a common cancer entity, which may interfere with survival in
relatively benign first primary cancers. We examined the hypothesis that immune dysfunction may contribute
to SPCs by assessing SPCs associated with known immune responsive skin cancers, invasive and in situ
squamous cell carcinoma, Kaposi sarcoma, and Merkel cell carcinoma. Cancers were identified from the
Swedish Cancer Registry from the year 1958 to 2015. Standardized relative risks were calculated bidirectionally
for any SPC after skin cancer and for skin cancer as SPC. Over 80,000 first primary cancers were identified for
each invasive and in situ squamous cell carcinoma of the skin. Bidirectional increased risks were observed for
26 cancers associated with invasive skin cancer; the Spearman rank correlation was 0.72 (P ¼ 4.6  10e5). The
highest bidirectional relative risks were for invasive and in situ skin cancer as SPCs (14.59 and 16.71, respec-
tively). Remarkably high risks for second in situ squamous cell carcinoma of the skin were found after Kaposi
sarcoma (685.68) and Merkel cell carcinoma (117.23). The high systematic bidirectional risks between immune
responsive skin cancers and most other cancers suggest that immune suppression is a key mechanism
contributing to an increased risk of SPCs.
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Squamous cell carcinoma (SCC) of the skin is among the most
frequently diagnosed form of cancer in fair-skinned pop-
ulations, and whose incidence rates have increased in recent
years (Green and Olsen, 2017; Hussain et al., 2010; Rees
et al., 2014). In addition to invasive SCC, intraepithelial (in
situ) SCCs of the skin, also known as Bowen’s disease, are
also common (Hussain et al., 2010). Although generally non-
fatal, treatment for SCC can be potentially disfiguring and the
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exposure to ultraviolet radiation is the main established risk
factor for SCC. Other risk factors include sun-sensitive skin,
immunosuppression, exposure to arsenic, glucocorticoids
and polycyclic hydrocarbons, and possibly smoking and
cutaneous papillomavirus infections (Green and Olsen,
2017; IARC, 2012b). Kaposi sarcoma (KS) and Merkel cell
carcinoma (MCC) are virus-associated tumors that affect the
skin and soft tissues (Zur Hausen, 2009). Human herpesvirus
8 is considered a necessary but insufficient cause of KS,
whereas Merkel cell polyomavirus is the cause of MCC (Zur
Hausen, 2009). In Sweden, both KS and MCC are diseases
that typically occur among elderly people, mainly men, but
in populations with high prevalence of HIV infection, KS and
MCC also affect younger individuals (Hussain et al., 2010; Ji
and Hemminki, 2007). Alike skin SCC, KS and MCC are more
common in immune deficiency conditions and immuno-
suppressed patients, and the risks for KS may be 200-fold
(Hemminki et al., 2012; Lanoy et al., 2010; Zur Hausen,
2009).
Skin SCC is not recorded by most national cancer regis-
tries, and thus, population-based epidemiology concerning
this common cancer, especially the in situ SCC, is limited
compared with many other cancers. Nevertheless, a sys-
tematic review was able to summarize results from 10 studies
reporting on second primary cancers (SPCs) after SCC and
found significant increases for cancers of the salivary glands,
lip, mouth, pharynx, and lung, and for melanoma and non-
Hodgkin lymphoma (Wheless et al., 2010). Previous resultsuthors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.
Table 1. Summary of the Cohort Followed
Summary of Cases Values
Total number of individuals followed 16.1 million
Number of invasive skin cancer 71,938
Median age at diagnosis, y 75 (64e81)1
SPCs after invasive skin cancer 25,108
Median follow-up time until SPC diagnosis, y 2.5 (1e6)
Number of in situ skin cancer 82,556
Median age at diagnosis, y 73 (65e80)
SPCs after in situ skin cancer 18,105
Median follow-up time until SPC diagnosis, y 5 (2e10)
Histologic Classification
Invasive Squamous
Cell Carcinoma
In Situ Squamous
Cell Carcinoma
Kaposi
Sarcoma
Merkel Cell
Carcinoma
PAD identification codes 146 144 446 566
Number of cancer diagnosis 71,938 82,556 597 1,011
Number of skin SPCs among:
all invasive skin cancer
9,148 9,340 57 38
all in situ skin cancer 5,284 18,559 28 7
squamous cell carcinoma 8,655 7,682 13 24
Kaposi sarcoma 12 35 38 0
Merkel cell carcinoma 19 11 0 5
Abbreviations: PAD, histology code; SPC, second primary cancer; y, years.
1Values in square bracket indicated interquartile range
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Multiple Skin Cancersfrom Swedish studies suggested that the risks for SPCs might
be somewhat similar between invasive and in situ SCC
(Hemminki and Dong, 2000). Data on SPCs related to MCC
and KS are sparse but some associations have been reported,
including with non-Hodgkin lymphoma and chronic lym-
phocytic leukemia (Kaae et al., 2010; Koljonen et al., 2015;
Tadmor et al., 2012; Zheng et al., 2019). Invasive and in
situ SCCs also share familial risks. SCC is a manifestation in
some very rare cancer syndromes affecting DNA repair
(xeroderma pigmentosum and Fanconi anemia subtypes),
chromosomal instability (Bloom and Werner syndrome),
transforming growth factor-b signaling, telomere mainte-
nance, and several other pathways (Green and Olsen, 2017;
Rahman, 2014). Genome-wide association studies on SCC
have identified 20 low-risk loci, many of which function in
pigmentation, immune regulation, or oncogenic pathways
(Green and Olsen, 2017).
In the present study, we focused on assessing risks of SPCs
in patients with invasive and in situ skin SCC, KS, and MCC,
and reciprocally, risk of these cancers as SPCs after any
cancer. We anticipate that the bidirectional results will help
to understand the underlying causes for SPCs. We wanted to
focus, in particular, on the recent challenging bidirectional
results on SPCs associated with myeloid neoplasms and non-
Hodgkin lymphoma that suggested that immunosuppression
contributed to the risk of SPC (Chattopadhyay et al., 2018a;
Chattopadhyay et al., 2018b). As immunosuppression is the
shared risk factor for SCC skin cancer, KS, and MCC, we
expect our results to be highly informative concerning im-
mune mechanisms in SPCs (Harms et al., 2018; IARC, 2012a;
Rama and Grinyo´, 2010; Rangwala and Tsai, 2011). Recent
data also suggest that these cancers are responsive to
immunotherapy (Colunga et al., 2018; Galanina et al., 2018;
Migden et al., 2018). We utilized data from the nationwideSwedish Cancer Registry covering the years 1958 through
to 2015.
RESULTS
Of the total 16.1 million individuals followed, 82,205
developed invasive skin cancer and 82,556 developed in situ
skin cancer by the end of 2015 (Table 1). Among the people
with invasive skin cancer, 25,108 later developed SPC with a
median time to SPC of 2.5 years. For in situ skin cancer pa-
tients, the number of SPC diagnosis was 18,105 with a longer
time to SPC of 5 years. Median age at SPC diagnosis was 75
after invasive skin cancer and 73 years after in situ skin
cancer. Age of diagnosis (median [interquartile range]) of
invasive SCC as SPC was 82 years (73e86) and for in situ SCC
it was 79 years (72e84). Time to invasive SCC as SPC was 7
years (3e13) and time to in situ SCC as SPC was 7 years
(3e15). Age-standardized incidence rates of SCC are shown
in Supplementary Figure S1. During the study period the
incidence of invasive SCC increased about 10 times and it
increased even more for in situ SCC, for which the rate sur-
passed the rate of invasive SCC at around 1990.
Bidirectional risks for invasive skin SCC with any cancer
are shown in Table 2. Column A shows the risks of SPC after
skin cancer. SPC of the in situ skin and invasive SCCs showed
the highest risks of 16.71 and 14.59, respectively. The overall
risk of SPC other than skin cancer was 1.41, with 23 SPCs of
significantly increased risk. Among the highest risks of indi-
vidual SPCs, the relative risks (RRs) increased more than 3-
fold for cancers of the upper aerodigestive tract (UAT; RR of
4.42), nose (3.09), and for melanoma (3.81), whereas anal,
connective tissue, and male and female genital SPCs, and
leukemia, Hodgkin and non-Hodgkin lymphoma had a more
than 2-fold excess risk. In column B, with the reciprocal
analyses, risks for SPC of the skin showed high risks,www.jidonline.org 49
Table 2. Risk of SPC after Invasive Skin SCC and Risk of Second Primary Invasive Skin SCC after Any Cancer
Cancer
A. Risk of SPCs after Invasive Skin SCC B. Risk of Invasive Skin SCC after Any Cancer
N RR Lower CI Upper CI P-value N RR Lower CI Upper CI P-value
UAT1 485 4.42 4.04 4.84 <0.0001 897 5.65 5.29 6.04 <0.0001
Esophagus1 104 1.75 1.44 2.12 <0.0001 33 1.65 1.17 2.32 0.004
Stomach1 388 1.56 1.41 1.72 <0.0001 153 1.19 1.02 1.40 0.031
Small intestine 34 1.34 0.96 1.89 0.0861 39 1.68 1.23 2.30 0.0012
Colorectum1 1,185 1.47 1.39 1.56 <0.0001 1,377 1.51 1.43 1.59 <0.0001
Anus1 33 2.69 1.91 3.80 <0.0001 32 2.17 1.53 3.07 <0.0001
Liver 228 1.17 1.03 1.33 0.0184 39 0.78 0.57 1.07 0.1187
Pancreas 203 1.14 0.99 1.31 0.063 26 0.64 0.44 0.94 0.0227
Nose1 26 3.09 2.09 4.56 <0.0001 51 5.02 3.81 6.60 <0.0001
Lung1 712 1.84 1.71 1.98 <0.0001 190 1.27 1.10 1.46 0.0011
Breast1 643 1.35 1.25 1.46 <0.0001 1,627 1.65 1.57 1.74 <0.0001
Cervix 31 1.25 0.88 1.78 0.2107 163 1.75 1.50 2.04 <0.0001
Endometrium1 142 1.39 1.18 1.64 0.0001 507 1.73 1.58 1.89 <0.0001
Ovary1 95 1.42 1.16 1.73 0.0007 138 1.30 1.10 1.53 0.0023
Other female genitals1 59 2.12 1.64 2.75 <.0001 52 1.72 1.31 2.25 <0.0001
Prostate1 1,829 1.20 1.15 1.26 <0.0001 2,884 1.53 1.47 1.59 <0.0001
Testis 5 1.77 0.73 4.27 0.2055 46 2.39 1.79 3.19 <0.0001
Other male genitals1 31 2.30 1.61 3.29 <0.0001 39 1.90 1.39 2.61 <0.0001
Kidney1 200 1.54 1.34 1.77 <0.0001 197 1.37 1.19 1.57 <0.0001
Urinary bladder1 542 1.83 1.68 1.99 <0.0001 691 1.72 1.59 1.85 <0.0001
Melanoma1 587 3.81 3.51 4.14 <0.0001 1,190 3.89 3.67 4.12 <0.0001
Skin (in situ)1 7,682 16.71 16.30 17.14 <0.0001 5,284 8.33 8.09 8.58 <0.0001
Skin (invasive)
Squamous cell1 8,655 14.59 14.25 14.93 <0.0001
Kaposi sarcoma1 13 2.69 1.55 4.67 0.0004 52 8.93 6.81 11.73 <0.0001
Merkel cell1 24 3.98 2.64 6.02 <0.0001 26 5.41 3.68 7.94 <0.0001
Eye1 17 1.65 1.02 2.67 0.0393 33 1.57 1.12 2.21 0.0095
Nervous system 94 1.08 0.88 1.32 0.4725 157 1.22 1.05 1.43 0.0113
Thyroid gland 33 1.28 0.91 1.80 0.1588 73 1.26 1.00 1.59 0.0463
Endocrine glands 41 0.83 0.61 1.13 0.2292 223 1.37 1.20 1.56 <0.0001
Bone 6 1.45 0.65 3.24 0.3667 13 1.57 0.91 2.70 0.1042
Connective tissue1 78 2.55 2.03 3.19 <0.0001 97 2.40 1.97 2.93 <0.0001
NHL1 445 2.55 2.32 2.80 <0.0001 840 5.02 4.69 5.38 <0.0001
Hodgkin lymphoma1 29 2.18 1.51 3.15 <0.0001 91 5.83 4.75 7.16 <0.0001
Multiple myeloma1 109 1.25 1.03 1.50 0.0228 106 1.84 1.52 2.22 <0.0001
Leukemia1 355 2.15 1.93 2.38 <0.0001 867 6.14 5.74 6.57 <0.0001
CUP1 366 1.58 1.43 1.75 <0.0001 115 1.60 1.33 1.92 <0.0001
All (without skin) 9,731 1.41 1.38 1.44 <0.0001 12,989 1.98 1.94 2.02 <0.0001
Boldface indicates that 95% CIs do not include RR of 1.00.
Abbreviations: CI, confidence interval; CUP, carcinoma of unknown primary; NHL, non-Hodgkin lymphoma; RR, relative risk; SPC, second primary cancer;
SCC, squamous cell carcinoma; UAT, upper aerodigestive tract.
1Both bidirectional RRs significantly increased.
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50including RR of 8.93 for second KS and 5.41 for second
MCC. The overall risk of SPC other than concordant skin was
1.98, with 29 significantly increased risks for SPC of the skin.
More than 5-fold increase in risk for SPC of the skin was
found when UAT (5.65) and nasal (5.02) cancers, Hodgkin
(5.83) and non-Hodgkin lymphoma (5.02), and leukemia
(6.14) were first cancers.
Bidirectional risks of SPC after in situ skin SCC (column
A) and of in situ skin SCC as SPC (column B) are shown in
Table 3. SPCs were increased at five non-skin sites, with an
overall RR of 1.22, which was partially explained by the
individual RRs that were below 1.00. The highest RRs were
for melanoma (1.90) and Hodgkin lymphoma (1.66). SPC in
situ SCC showed an RR of 18.84, twice as high as the RR ofJournal of Investigative Dermatology (2020), Volume 1409.88 for invasive skin cancer; the RR for KS was 4.45. The
overall RR for in situ skin cancer as SPC was 2.00,
contributed by increased risks after 25 different cancers
other than skin cancers. In situ skin cancer risk was
increased to 6.05 after leukemia, to 4.73 after melanoma, to
4.61 after non-Hodgkin lymphoma, and to 4.65 after
Hodgkin lymphoma. Remarkably high risks for second in
situ SCC cancer were found after KS (685.68) and MCC
(117.23).
In Table 4, we assessed the concordance for bidirectional
SPC risks from Tables 2 and 3, (shown by superscript number
1). In Table 2, RRs for 26 SPC pairs were both significant, that
is, remarkably high RR of 4.42 for UAT cancer as SPC and
5.65 for invasive skin cancer after UAT cancer, for nasal
Table 3. Risk of SPC after In Situ Skin SCC and Risk of Second Primary In Situ Skin SCC after Any Cancer
A. Risk of SPCs after In Situ Skin SCC
B. Risk of Second Primary In Situ Skin SCC after
Invasive Cancer
Cancer N RR Lower CI Upper CI P-value N RR Lower CI Upper CI P-value
UAT 214 1.19 1.04 1.36 0.0121 826 3.50 3.27 3.75 <0.0001
Esophagus 89 0.87 0.71 1.08 0.2046 29 1.12 0.78 1.61 0.5384
Stomach 272 0.73 0.65 0.82 <0.0001 180 1.15 1.00 1.33 0.0573
Small intestine 43 0.99 0.73 1.34 0.9594 53 1.55 1.18 2.03 0.0015
Colorectum 1,252 0.97 0.92 1.03 0.292 1,795 1.49 1.42 1.56 <0.0001
Anus 18 0.88 0.55 1.40 0.5778 47 2.40 1.80 3.19 <0.0001
Liver 211 0.65 0.57 0.75 <0.0001 68 1.09 0.86 1.38 0.4761
Pancreas 246 0.83 0.73 0.94 0.0028 42 0.84 0.62 1.14 0.268
Nose 16 1.18 0.72 1.94 0.5049 37 2.56 1.85 3.53 <0.0001
Lung 603 0.88 0.81 0.96 0.0023 313 1.50 1.34 1.67 <0.0001
Breast 918 0.96 0.90 1.03 0.258 2,952 1.60 1.54 1.66 <0.0001
Cervix 34 0.67 0.48 0.94 0.0199 271 1.43 1.27 1.61 <0.0001
Endometrium 172 0.76 0.66 0.89 0.0004 851 1.57 1.46 1.68 <0.0001
Ovary 139 0.93 0.78 1.09 0.3629 297 1.45 1.29 1.62 <0.0001
Other female genitals 63 1.15 0.90 1.48 0.2589 77 1.60 1.28 2.00 <0.0001
Prostate 1,508 0.85 0.80 0.89 <0.0001 3,224 1.82 1.75 1.89 <0.0001
Testis 66 2.13 1.67 2.71 <0.0001
Other male genitals 15 0.93 0.56 1.55 0.7761 37 1.71 1.24 2.36 0.0011
Kidney 180 0.82 0.70 0.94 0.0064 324 1.49 1.33 1.66 <0.0001
Urinary bladder 426 0.86 0.78 0.94 0.0015 924 1.54 1.44 1.64 <0.0001
Melanoma1 476 1.90 1.73 2.08 <0.0001 2,132 4.73 4.53 4.94 <0.0001
SCC (in situ) 1 18,559 18.84 18.52 19.16 <0.0001
Skin (invasive)
SCC1 5,037 9.88 9.59 10.19 <0.0001 7,682 16.71 16.30 17.14 <0.0001
Kaposi sarcoma1 28 4.45 3.02 6.57 <0.0001 35 685.68 482.32 974.81 <0.0001
Merkel cell 6 1.21 0.54 2.71 0.6454 11 117.23 64.48 213.14 <0.0001
Eye 16 0.91 0.55 1.48 0.696 39 1.26 0.92 1.73 0.1484
Nervous system 112 0.71 0.59 0.86 0.0004 255 1.29 1.14 1.46 <0.0001
Thyroid gland 37 0.86 0.62 1.18 0.3469 117 1.27 1.06 1.52 0.0098
Endocrine glands 63 0.69 0.54 0.89 0.0039 403 1.65 1.50 1.82 <0.0001
Bone 7 1.01 0.48 2.13 0.9717 19 1.43 0.91 2.24 0.1181
Connective tissue1 70 1.40 1.10 1.77 0.0058 132 2.17 1.83 2.57 <0.0001
NHL1 388 1.32 1.19 1.45 <0.0001 1,093 4.61 4.34 4.90 <0.0001
Hodgkin lymphoma1 36 1.66 1.20 2.31 0.0025 124 4.65 3.90 5.54 <0.0001
Multiple myeloma 115 0.78 0.65 0.93 0.0067 160 2.10 1.80 2.45 <0.0001
Leukemia1 322 1.20 1.08 1.35 0.0009 1,156 6.05 5.71 6.41 <0.0001
CUP 386 1.00 0.90 1.10 0.9604 127 1.40 1.18 1.67 0.0001
All (without skin) 8,447 1.22 1.18 1.24 <0.0001 18,173 2.00 1.96 2.03 <0.0001
Boldface indicates that 95% CIs do not include RR of 1.00.
Abbreviations: CI, confidence interval; CUP, carcinoma of unknown primary; NHL, non-Hodgkin lymphoma; RR, relative risk; SPC, second primary cancer;
SCC, squamous cell carcinoma; UAT, upper aerodigestive tract.
1Both bidirectional RRs significantly increased.
S Chattopadhyay et al.
Multiple Skin Cancerscancer (3.09 and 5.02) and for melanoma (3.81 and 3.89).
The Spearman rank correlation was 0.72 (P ¼ 4.6  10e5) for
these 26-paired RRs (Table 4). The correlation was even
higher for the 29-paired RRs between second invasive and in
situ skin cancers (rho ¼ 0.90, P ¼ 4.2  10e11). Some of the
other shown correlations were also highly significant.
SPC risks after KS and risk of second primary KS after other
cancers are reported in the top panel of Table 5 for cancers
other than skin cancer; the overall risks were 1.71 and 1.88,
respectively. Despite the small case number, a bidirectional
increase in risk was observed for all hematological cancers:
Hodgkin lymphoma (21.00 and 9.33), non-Hodgkin lym-
phoma (5.95 and 7.09), multiple myeloma (3.73 and 6.31),and leukemia (2.59 and 3.75). Among other cancers, SPC of
liver (2.31) and cancer of unknown primary (2.43) had excess
risk after KS. Second primary KS was observed with an excess
risk after lung (2.68), testicular (8.65), bladder (2.09), and
connective tissue cancers (14.87).
MCC was associated with a high overall risk of subsequent
SPC, RR of 1.90, and 1.81 for MCC as SPC (Table 6). Cancers
of UAT, endocrine glands, and melanoma were associated
with a bidirectional risk. Additionally, RRs for SPC of the liver
(3.11), endometrium (3.10), and kidney (4.81) were
increased. The reciprocal analyses showed an excess risk of
second primaryMCC after prostate (1.92) and bladder cancers
(2.19), non-Hodgkin lymphoma (4.74), and leukemia (8.73).www.jidonline.org 51
Table 4. Linear Ranked Correlations among Skin SCC and Other Cancers between Pairs of First and SPCs Shown in
Tables 2 and 3
SPC after Invasive SCC Invasive SCC as SPC SPC after in situ SCC In situ SCC as SPC
SPC after invasive SCC 1 — — —
Invasive SCC as SPC 0.72
(P ¼ 4.6  10e5)
26
1 — —
SPC after in situ
SCC
0.89
(P ¼ 2.4  10e3)
8
0.56
(P ¼ 0.15)
8
—
1
—
In situ
SCC as SPC
0.72
(P ¼ 1.1  10e4)
24
0.90
(P ¼ 4.2  10e11)
29
0.57
(P ¼ 0.20)
7
1
Each cell represents the Spearman rho, two-tailed test P-value and number of cancer pairs with significantly increased RRs.
Abbreviations: RR, relative risk; SPC, second primary cancer; SCC, squamous cell carcinoma.
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52DISCUSSION
The present study carries out a systematic bidirectional
analysis of SPCs after invasive and in situ skin cancers and of
skin cancers as SPCs after any cancers. Treatment is often
regarded as an important risk factor for SPC, but in the case of
SPC after skin cancers, other factors need to be considered, as
their treatment is primarily surgery and infrequently radio-
therapy. SCC of the skin, KS, and MCC are all cancers
frequently occurring in immunosuppressed individuals, and
the present bidirectional analyses suggest that induced (by
the tumor or treatment) or inherent immune dysfunction may
be a common shared mechanism for SPC, especially for non-
Hodgkin lymphoma, and for kidney, UAT (particularly lip),Table 5. Risk of SPC after KS and that of Second Primary
A. Risk of Invasive SPCs after KS
Cancer N RR Lower CI Upper CI
UAT 3 2.26 0.73 7.01
Stomach 5 1.38 0.57 3.31
Colorectum 14 1.48 0.88 2.51
Liver 6 2.31 1.04 5.15
Pancreas 2 0.86 0.21 3.43
Lung 2 0.45 0.11 1.79
Breast 4 1.14 0.43 3.05
Endometrium 0
Prostate 21 1.06 0.69 1.63
Testis 0
Kidney 3 1.76 0.57 5.46
Urinary bladder 4 1.20 0.45 3.20
Melanoma 1 0.63 0.09 4.50
Endocrine glands 1 1.59 0.22 11.30
Connective tissue 1 2.68 0.38 19.06
NHL1 12 5.95 3.38 10.48
Hodgkin lymphoma1 4 21.00 7.88 56.00
Multiple myeloma1 4 3.73 1.40 9.93
Leukemia1 5 2.59 1.08 6.22
CUP 7 2.43 1.16 5.10
All (without skin) 103 1.71 1.43 1.96
Boldface indicates that 95% CIs do not include RR of 1.00.
Abbreviations: CI, confidence interval; CUP, carcinoma of unknown primary;
SPC, second primary cancer; SCC, squamous cell carcinoma; UAT, upper aero
1Both bidirectional RRs significantly increased.
Journal of Investigative Dermatology (2020), Volume 140genital, stomach, and colorectal cancers (Harms et al., 2018;
Hortlund et al., 2017; IARC, 2012a; Rama and Grinyo´, 2010;
Rangwala and Tsai, 2011). For example, in Table 2, a large
majority (26 of 36) of bidirectional comparisons between RRs
for cancer X as SPC and skin SCC as SPC after cancer X were
mutually significant. Many of the correlation coefficients
were high and highly significant irrespective of whether
invasive or in situ SCC skin cancers were considered as first
cancer or SPC. Although we cannot exclude the role of other
contributing factors for SPC, no known lifestyle related risk
factors are known to exert risks at such a large number of
diverse cancers. Additionally, it is likely that treatment of first
primary cancer contributed to the risks of skin cancer as SPC,KS after Other Invasive Cancers
B. Risk of Second Primary KS after Invasive Cancers
P-value N RR Lower CI Upper CI P-value
0.1576 2 1.09 0.27 4.37 0.903
0.4737 3 1.58 0.51 4.91 0.4301
0.1399 12 1.37 0.77 2.43 0.2832
0.0401 0
0.8287 0
0.256 4 2.68 1.00 7.18 0.0492
0.7867 8 1.40 0.69 2.85 0.3546
4 2.40 0.89 6.48 0.0843
0.7811 28 1.41 0.96 2.08 0.0803
3 8.65 2.77 27.02 0.0002
0.3273 1 0.67 0.09 4.78 0.6917
0.7163 8 2.09 1.04 4.21 0.0385
0.6487 2 0.95 0.24 3.82 0.9445
0.6422 3 2.29 0.73 7.12 0.1535
0.3235 6 14.87 6.65 33.24 <0.0001
<0.0001 10 7.09 3.79 13.27 <0.0001
<0.0001 2 9.33 2.33 37.37 0.0016
0.0085 4 6.31 2.36 16.87 0.0002
0.0335 5 3.75 1.55 9.05 0.0033
0.0189 1 1.25 0.18 8.91 0.822
<0.0001 113 1.88 1.54 2.31 <0.0001
KS, Kaposi sarcoma; NHL, non-Hodgkin lymphoma; RR, relative risk;
digestive tract.
Table 6. Risk of SPC after MCC and that of Second Primary MCC after Other Invasive Cancers
A. Risk of Invasive SPCs after MCC B. Risk of Second Primary MCC after Invasive Cancers
Cancer N RR Lower CI Upper CI P-value N RR Lower CI Upper CI P-value
UAT1 3 4.04 1.30 12.54 0.0155 6 3.92 1.75 8.77 0.0009
Colorectum 5 0.89 0.37 2.13 0.7853 12 1.25 0.71 2.23 0.4384
Liver 4 3.11 1.17 8.28 0.0233 0
Pancreas 2 1.74 0.43 6.94 0.4354 0
Lung 4 1.55 0.58 4.12 0.3838 2 1.42 0.35 5.70 0.6207
Breast 2 0.46 0.11 1.84 0.2709 16 1.25 0.76 2.08 0.3796
Cervix 0 1 0.85 0.12 6.04 0.8694
Endometrium 3 3.10 1.00 9.62 0.0499 6 1.55 0.69 3.48 0.2902
Prostate 9 1.13 0.59 2.16 0.7234 28 1.92 1.28 2.87 0.0016
Kidney 4 4.81 1.81 12.82 0.0017 0
Urinary bladder 1 0.47 0.07 3.35 0.4525 9 2.19 1.13 4.23 0.0204
Melanoma1 7 6.05 2.89 12.70 <0.0001 10 3.30 1.76 6.18 0.0002
Nervous system 1 1.72 0.24 12.18 0.5895 2 1.54 0.38 6.18 0.5426
Endocrine glands1 4 11.78 4.42 31.39 <0.0001 7 4.04 1.91 8.53 0.0002
NHL 3 2.31 0.74 7.15 0.1479 8 4.74 2.35 9.54 <0.0001
Leukemia 3 2.59 0.83 8.02 0.0999 12 8.73 4.92 15.50 <0.0001
CUP 4 2.33 0.87 6.21 0.0907 0
All (without skin) 66 1.90 1.68 2.17 <0.0001 121 1.81 1.48 2.21 <0.0001
Boldface indicates that 95% CIs do not include RR of 1.00.
Abbreviations: CI, confidence interval; CUP, carcinoma of unknown primary; MCC, Merkel cell carcinoma; NHL, non-Hodgkin lymphoma; RR, relative risk;
SPC, second primary cancer; SCC, squamous cell carcinoma; UAT, upper aerodigestive tract.
1Both bidirectional RRs significantly increased.
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risks for skin cancer as SPC (column B in Tables 2 and 3) than
for any SPC after skin cancer.
Limitations of the study include lack of data on individuals
who have been immunosuppressed for medical reasons. A
recent Swedish study used medical records from 1964 on-
wards and identified a total of 12,400 organ transplant re-
cipients who had been diagnosed with 990 non-melanoma
skin cancers (Hortlund et al., 2017). This is a modest
proportion of the 82,000 SCC skin cancers of the present
study. Immune suppression because of HIV may also lead to a
spectrum of cancers, but the number of known HIV patients
is estimated at 7,000 in the total population of 10 million
Swedes, and with the current mediation, cancer
risk is controlled in these patients (https://www.
folkhalsomyndigheten.se/the-public-health-agency-of-sweden/
living-conditions-and-lifestyle/hiv-and-stis/). Another prob-
lem, related to the study design, is surveillance bias, which is
very difficult to control (Hemminki et al., 2017). However, it
has not reached magnitudes of risk found in the present study
and it diminishes when the time between first medical con-
tact and the diagnostic contact is extended. Finally, although
targeted therapies using drugs such as BRAF inhibitors may
have indications in SCC treatment, it is unclear whether such
treatments have been introduced in Sweden.
What is known about mechanisms of SPCs not related to
therapy or shared environmental and/or lifestyle factors?
Immunosuppressed organ transplantation patients have an
increased risk of KS (up to 200-fold), SCC in the skin, oral
cavity, and pharynx (i.e., parts of UAT), and of non-Hodgkin
lymphoma and MCC (some 20-fold), and a somewhat lower
but still increased risk of kidney cancer, melanoma, leuke-
mia, and anogenital cancers (some 5-fold) (Birkeland et al.,1995; Hortlund et al., 2017; Rama and Grinyo´, 2010;
Wimmer et al., 2007). An increased incidence of certain
viral-associated cancers in immunosuppressed populations is
associated with viral reactivation, which is common in SCC,
non-Hodgkin lymphoma, KS, and MCC (Rangwala and Tsai,
2011); these cancers are also increased in HIV infected
populations (Hessol et al., 2018). Anogenital cancers are
associated with human papillomavirus infection, particularly
related to the alpha genus of mucosal human papillomavirus
types 16 and 18 (Oh and Weiderpass, 2014; Zur Hausen,
2009). Of note, cervical cancer was only increased in some
analyses, whereas other female genital cancers showed
higher risks. The reason may be a much lower diagnostic age
of cervical cancer compared with most of all other cancers.
In skin, SCC the beta genus human papillomavirus may be
playing a role, whereas ultraviolet irradiation would be an
example of a non-infective mechanism (Bouwes Bavinck
et al., 2018; IARC, 2012a). In Hodgkin and non-Hodgkin
lymphoma, Epstein-Barr virus has been proposed to be a
key infective causative agent (Scha¨fer et al., 2015). KS-
associated herpes virus has a wide tropism including B
cells, endothelial cells, fibroblasts, and epithelial cells,
whereas for MCC papilloma virus the tropism is not well
known (Scha¨fer et al., 2015). For these SPCs, the first primary
cancer, or its treatment, may suppress immune function in
other parts of the body and facilitate viral reactivation. mTOR
inhibitors have been used with variable success to intervene
with viral reactivation (de Fijter, 2017).
However, for many other SPCs, an infective etiology is
not known, but first primary cancers may negatively influ-
ence immune function through chronic inflammation and
suppression of cellular defense mechanisms, which may
mimic iatrogenic immune suppression (Friman et al., 2016).www.jidonline.org 53
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54In order for tumors to evade immune surveillance, they need
mechanisms to suppress the immune response (Munn and
Bronte, 2016). For example, NF-kB signaling is a master
regulator of cancer-associated chronic inflammation,
contributing to immunosuppression through induction of
proinflammatory mediators and activation of immune sup-
pressor cells (Schreiber et al., 2005; Taniguchi and Karin,
2018; Wang and DuBois, 2015). Myeloid-derived suppres-
sor cells, tumor-associated macrophages, N2 neutrophils,
CD8þ suppressors, and regulatory T cells can produce che-
mokines, cytokines, growth factors, and proteases, which can
contribute to immune response and its suppression
(Shalapour and Karin, 2015). Consequently, immunotherapy
is a promising approach for the treatment of skin tumor types
considered here, and as it aims at reversing the above pro-
cesses, it will be exciting to observe whether the risk of SPCs
decreases (Colunga et al., 2018; Galanina et al., 2018;
Migden et al., 2018; Nghiem et al., 2016).
Overall, the results showed that the risks for SPC were
higher after invasive SCC compared with in situ skin SCC; and
this was true for each SPC, with exception of in situ skin
cancer and KS. The reason may be that in situ lesions are
likely to be small and less immunosuppressive than invasive
skin cancers, and consequently, the median time to SPC was
two times longer after in situ than after invasive first primary
cancer. Curiously, the RRs for many SPCs were significantly
below 1.00 after in situ skin cancer for unknown reasons. RRs
for skin cancer as SPC were equal for invasive and in situ SPC,
which appeared not to depend on individual first cancers. The
exceptions were RRs for SPCs of the skin, which were higher
for in situ SCCs than for invasive types, and particularly after
KS (685.68 vs. 8.93) and MCC (117.23 vs. 5.41). The reason
for this difference may be that the patients diagnosed with KS
and MCC are under surveillance, particularly for skin lesions,
whereby early tumors are primarily detected.
KS and MCC are rare cancers, but high risks of KS have
been observed in HIV infected persons (Hessol et al., 2018).
In the present analysis, we showed high bidirectional risks
between KS and all hematological malignancies. The KS-
associated human herpesvirus 8 is also known to cause rare
primary effusion lymphoma and multicentric Castelman
disease, but these are too rare to alone explain the associa-
tions with hematological malignancies (IARC, 2012a). MCC
was increased as SPC after hematological malignancies, but
bidirectional associations were observed with UAT cancer,
melanoma, and endocrine gland tumors.
In conclusion, the high systematic bidirectional risks be-
tween skin cancers, known to be associated with immuno-
suppression, and most other cancers suggest that
immunologic factors are key mechanisms contributing to an
increased risk of SPCs. Of note, such epidemiologic data
would immediately suggest that immunotherapy could be an
attractive treatment option for not only skin cancers (Colunga
et al., 2018; Galanina et al., 2018; Migden et al., 2018;
Nghiem et al., 2016) but also SPCs arising in skin cancer
patients.
MATERIALS AND METHODS
Data for our study were obtained from the Swedish Family-Cancer
Database, which includes information on the residents of SwedenJournal of Investigative Dermatology (2020), Volume 140organized in families (Hemminki et al., 2010). Individuals were
linked to the Swedish cancer register, cause of death register, migra-
tion register, and population census with a unique identifier, andwere
queried for first and any subsequent primary cancers (Hemminki
et al., 2010). The database records cancers according to the inter-
national classification of diseases, seventh and later revisions; the
code for skin cancer was 201. Until the end of 2015, more than 2.1
million cancers were recorded among 16.1 million individuals. From
this data, we identified all individuals who were diagnosed with in
situ skin cancer and invasive SCC, KS, and MCC with histologic
identifier (WHO/HS/CANC/24.1 Histology Code, ‘PAD’) 144, 146,
446, and 566, respectively. If two of these cancers were reported
synchronously, the first report was considered; in rare instances when
the data of diagnoses were reported on the same date, invasive SCC
was considered the first cancer. All skin cancers reported to the
Cancer Registry are histologically verified, as are practically all other
cancers (Centre for Epidemiology, 2013). We followed all newly
diagnosed in situ and invasive skin cancer patients for diagnosis of
any of the 32 different invasive SPCs. The follow-up started on January
1, 1958, and terminated at diagnosis of SPC, emigration, death, or
December 31, 2015, whichever occurred earliest.
SPCs diagnosed after both in situ and invasive skin cancers were
investigated separately. RRs of SPCs were assessed by means of
incidence rate ratios of SPC among skin cancer survivors against risk
of that cancer in the general population. For the bidirectional ana-
lyses, RRs for skin cancers were calculated as SPCs after any primary
cancer. Person-years and SPCs were categorized according to age (5-
year bands), sex, socioeconomic index (six groups), region (four
groups), and calendar year. For the estimation of RRs, Poisson
regression was used after a point process and corresponding confi-
dence intervals for 5% level of significance. Fixed effects general-
ized linear multivariate model was used with the aforementioned
regressors, including age group, sex, calendar period, residential
area, and socioeconomic status, to adjust for potential confounding.
Linear ranked correlations among skin SCC and other cancers be-
tween pairs of first and SPC were assessed by calculating Spearman
rho with two-tailed test for P-value.
The study was approved by the Ethical Committee of Lund Uni-
versity, Sweden, without requirement for informed consent, and was
conducted in accordance with the tenets of the Declaration of
Helsinki. People could choose to opt out of the study, which was
advertised in major newspapers, before the research database was
constructed. The project database is located at the Center for Pri-
mary Health Care Research in Malmo¨, Sweden. All statistical ana-
lyses were done with SAS, version 9.4.Data availability statement
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register/halsodataregister/cancerregistret/inenglish).
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Supplementary Figure S1. Age-standardized incidence rates of invasive and
in situ SCC according to the Swedish Cancer Registry. SCC, squamous cell
carcinoma.
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